The Pfenex Expression Technology platform is unique in its ability to express complex antibody derivatives and other engineered binding modalities. These complex modalities have the potential for greater specificity, improved side effect profiles and ultimately successful therapeutic outcomes making them the focus of current biopharmaceutical development. We believe that our focused discovery and development engine positions us well to be a leader in the space.
In pursuit of novel wholly owned product candidates, Pfenex has established a collaboration with a third-party technology platform company who is screening Pfenex selected and validated biological targets with its novel binding modality library in an effort to identify potential lead product candidates. Those candidates, PF91X, will be transferred to Pfenex and could become wholly owned product candidates developed by Pfenex.